JP2013534426A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013534426A5 JP2013534426A5 JP2013518876A JP2013518876A JP2013534426A5 JP 2013534426 A5 JP2013534426 A5 JP 2013534426A5 JP 2013518876 A JP2013518876 A JP 2013518876A JP 2013518876 A JP2013518876 A JP 2013518876A JP 2013534426 A5 JP2013534426 A5 JP 2013534426A5
- Authority
- JP
- Japan
- Prior art keywords
- days
- bleeding
- item
- composition
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 95
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 88
- 229920001184 polypeptide Polymers 0.000 claims description 87
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 87
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 65
- 108010076282 Factor IX Proteins 0.000 claims description 65
- 229960004222 factor ix Drugs 0.000 claims description 65
- 230000000694 effects Effects 0.000 claims description 53
- 208000032843 Hemorrhage Diseases 0.000 claims description 44
- 208000034158 bleeding Diseases 0.000 claims description 44
- 230000000740 bleeding effect Effects 0.000 claims description 44
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 29
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 23
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 21
- 238000001356 surgical procedure Methods 0.000 claims description 19
- 238000011084 recovery Methods 0.000 claims description 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 11
- 230000000069 prophylactic effect Effects 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 208000014674 injury Diseases 0.000 claims description 7
- 230000008733 trauma Effects 0.000 claims description 7
- 210000003205 muscle Anatomy 0.000 claims description 6
- 238000007917 intracranial administration Methods 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 208000034656 Contusions Diseases 0.000 claims description 4
- 206010028024 Mouth haemorrhage Diseases 0.000 claims description 4
- 206010051297 Soft tissue haemorrhage Diseases 0.000 claims description 4
- 208000012310 mouth bleeding Diseases 0.000 claims description 4
- 206010072043 Central nervous system haemorrhage Diseases 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 230000036470 plasma concentration Effects 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 claims description 2
- 206010018276 Gingival bleeding Diseases 0.000 claims description 2
- 206010061249 Intra-abdominal haemorrhage Diseases 0.000 claims description 2
- 206010061298 Mucosal haemorrhage Diseases 0.000 claims description 2
- 206010028309 Muscle haemorrhage Diseases 0.000 claims description 2
- 206010034827 Pharyngeal haemorrhage Diseases 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 208000001780 epistaxis Diseases 0.000 claims description 2
- 208000030304 gastrointestinal bleeding Diseases 0.000 claims description 2
- 208000011759 gum bleeding Diseases 0.000 claims description 2
- 208000002085 hemarthrosis Diseases 0.000 claims description 2
- 208000006750 hematuria Diseases 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 210000001503 joint Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000001835 viscera Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 33
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 206010038980 Retroperitoneal haemorrhage Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 4
- 101150050927 Fcgrt gene Proteins 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- 238000005670 sulfation reaction Methods 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000029836 Inguinal Hernia Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000007428 craniotomy Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 229960000027 human factor ix Drugs 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000013150 knee replacement Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000000574 retroperitoneal space Anatomy 0.000 description 1
- 238000007483 tonsillectomy Methods 0.000 description 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36306410P | 2010-07-09 | 2010-07-09 | |
| US61/363,064 | 2010-07-09 | ||
| US201061424555P | 2010-12-17 | 2010-12-17 | |
| US61/424,555 | 2010-12-17 | ||
| US201161430819P | 2011-01-07 | 2011-01-07 | |
| US61/430,819 | 2011-01-07 | ||
| US201161438572P | 2011-02-01 | 2011-02-01 | |
| US61/438,572 | 2011-02-01 | ||
| US201161442079P | 2011-02-11 | 2011-02-11 | |
| US61/442,079 | 2011-02-11 | ||
| US201161470951P | 2011-04-01 | 2011-04-01 | |
| US61/470,951 | 2011-04-01 | ||
| PCT/US2011/043569 WO2012006624A2 (en) | 2010-07-09 | 2011-07-11 | Factor ix polypeptides and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015224436A Division JP2016034973A (ja) | 2010-07-09 | 2015-11-17 | 第ｉｘ因子ポリペプチドおよびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013534426A JP2013534426A (ja) | 2013-09-05 |
| JP2013534426A5 true JP2013534426A5 (enExample) | 2014-08-28 |
Family
ID=45441870
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013518876A Pending JP2013534426A (ja) | 2010-07-09 | 2011-07-11 | 第ｉｘ因子ポリペプチドおよびその使用方法 |
| JP2015224436A Pending JP2016034973A (ja) | 2010-07-09 | 2015-11-17 | 第ｉｘ因子ポリペプチドおよびその使用方法 |
| JP2016218597A Withdrawn JP2017036328A (ja) | 2010-07-09 | 2016-11-09 | 第ｉｘ因子ポリペプチドおよびその使用方法 |
| JP2018218122A Withdrawn JP2019023242A (ja) | 2010-07-09 | 2018-11-21 | 第ｉｘ因子ポリペプチドおよびその使用方法 |
| JP2022012817A Pending JP2022044828A (ja) | 2010-07-09 | 2022-01-31 | 第ｉｘ因子ポリペプチドおよびその使用方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015224436A Pending JP2016034973A (ja) | 2010-07-09 | 2015-11-17 | 第ｉｘ因子ポリペプチドおよびその使用方法 |
| JP2016218597A Withdrawn JP2017036328A (ja) | 2010-07-09 | 2016-11-09 | 第ｉｘ因子ポリペプチドおよびその使用方法 |
| JP2018218122A Withdrawn JP2019023242A (ja) | 2010-07-09 | 2018-11-21 | 第ｉｘ因子ポリペプチドおよびその使用方法 |
| JP2022012817A Pending JP2022044828A (ja) | 2010-07-09 | 2022-01-31 | 第ｉｘ因子ポリペプチドおよびその使用方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (13) | US9670475B2 (enExample) |
| EP (3) | EP2590668A4 (enExample) |
| JP (5) | JP2013534426A (enExample) |
| KR (5) | KR20230156435A (enExample) |
| CN (1) | CN103140237A (enExample) |
| AU (5) | AU2011274414B2 (enExample) |
| BR (1) | BR112013000650A8 (enExample) |
| CA (1) | CA2804274A1 (enExample) |
| CL (1) | CL2013000058A1 (enExample) |
| DK (1) | DK3552619T3 (enExample) |
| EA (2) | EA028067B1 (enExample) |
| FI (1) | FI3552619T3 (enExample) |
| IL (3) | IL223990B (enExample) |
| LT (1) | LT3552619T (enExample) |
| MX (3) | MX375112B (enExample) |
| MY (2) | MY166954A (enExample) |
| NZ (1) | NZ605348A (enExample) |
| PL (1) | PL3552619T3 (enExample) |
| PT (1) | PT3552619T (enExample) |
| RS (1) | RS67366B1 (enExample) |
| SG (3) | SG10201913700SA (enExample) |
| UA (2) | UA115120C2 (enExample) |
| WO (1) | WO2012006624A2 (enExample) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| WO2010091122A1 (en) | 2009-02-03 | 2010-08-12 | Amunix, Inc. | Extended recombinant polypeptides and compositions comprising same |
| EP2470559B1 (en) | 2009-08-24 | 2017-03-22 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
| EA028067B1 (ru) | 2010-07-09 | 2017-10-31 | Байоджен Хемофилия Инк. | Способы контроля или предотвращения кровотечения или эпизодов кровотечения |
| DK2591099T3 (da) | 2010-07-09 | 2021-02-15 | Bioverativ Therapeutics Inc | Kimære koagulationsfaktorer |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP4108671B1 (en) | 2010-10-01 | 2024-11-20 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
| US10656167B2 (en) | 2011-07-25 | 2020-05-19 | Bioverativ Therapeutics Inc. | Assays to monitor bleeding disorders |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| ES2911677T3 (es) | 2011-10-03 | 2022-05-20 | Modernatx Inc | Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos |
| MX2014007233A (es) | 2011-12-16 | 2015-02-04 | Moderna Therapeutics Inc | Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados. |
| EP3453402B1 (en) * | 2012-01-12 | 2021-07-21 | Bioverativ Therapeutics Inc. | Reducing immunogenicity against factor viii in individuals undergoing factor viii therapy |
| HUE043537T2 (hu) | 2012-02-15 | 2019-08-28 | Bioverativ Therapeutics Inc | Rekombináns VIII faktor fehérjék |
| PT2814840T (pt) | 2012-02-15 | 2020-01-28 | Bioverativ Therapeutics Inc | Composições de fator viii e métodos de produção e utilização das mesmas |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| EP2836518B1 (en) | 2012-04-11 | 2019-01-02 | Bioverativ Therapeutics Inc. | Methods of detecting glycosaminoglycans |
| WO2013185113A1 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Procoagulant compounds |
| HK1207591A1 (en) | 2012-06-08 | 2016-02-05 | Biogen Ma Inc. | Chimeric clotting factors |
| EP2877202A4 (en) | 2012-07-25 | 2016-06-01 | Biogen Ma Inc | BLOOD FACTORY MONITOR TEST AND USES THEREOF |
| WO2014052490A1 (en) * | 2012-09-25 | 2014-04-03 | Biogen Idec Ma Inc. | Methods of using fix polypeptides |
| EP2908847B1 (en) * | 2012-10-18 | 2022-03-30 | Bioverativ Therapeutics Inc. | Methods of using a fixed dose of a clotting factor |
| JP2015536148A (ja) * | 2012-11-20 | 2015-12-21 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 改変第ｉｘ因子タンパク質についての方法および組成物 |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| US10717965B2 (en) | 2013-01-10 | 2020-07-21 | Gloriana Therapeutics, Inc. | Mammalian cell culture-produced neublastin antibodies |
| HUE063051T2 (hu) | 2013-02-15 | 2023-12-28 | Bioverativ Therapeutics Inc | Optimalizált VIII. faktor gén |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| TWI788044B (zh) * | 2013-03-15 | 2022-12-21 | 美商百歐維拉提夫治療公司 | 因子ｉｘ多肽調配物 |
| TW202003554A (zh) | 2013-08-14 | 2020-01-16 | 美商百歐維拉提夫治療公司 | 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途 |
| ES2900425T3 (es) | 2013-09-25 | 2022-03-16 | Bioverativ Therapeutics Inc | Métodos de inactivación vírica en columna |
| WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| EP3082848B1 (en) | 2013-12-06 | 2023-10-18 | Bioverativ Therapeutics Inc. | Population pharmacokinetics tools and uses thereof |
| WO2015095809A1 (en) | 2013-12-20 | 2015-06-25 | Biogen Idec Ma Inc. | Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality |
| CN105848669A (zh) * | 2013-12-23 | 2016-08-10 | 杰特有限公司 | 用于血友病的预防性治疗的包含因子ix的融合蛋白及其方法 |
| US20160347787A1 (en) | 2014-02-04 | 2016-12-01 | Biogen Ma Inc. | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
| SG10201913735SA (en) * | 2014-03-24 | 2020-03-30 | Bioverativ Therapeutics Inc | Lyophilized factor ix formulations |
| WO2016004113A1 (en) | 2014-06-30 | 2016-01-07 | Biogen Ma Inc. | Optimized factor ix gene |
| MA40864A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères |
| JP6909203B2 (ja) * | 2015-08-03 | 2021-07-28 | バイオベラティブ セラピューティクス インコーポレイテッド | 第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法 |
| ES2926585T3 (es) | 2016-02-01 | 2022-10-27 | Bioverativ Therapeutics Inc | Genes de Factor VIII optimizados |
| EP4343774A3 (en) | 2016-04-15 | 2024-06-05 | Takeda Pharmaceutical Company Limited | Method and apparatus for providing a pharmacokinetic drug dosing regiment |
| TW201739448A (zh) * | 2016-05-06 | 2017-11-16 | 安成生物科技股份有限公司 | 用於治療及/或預防血液相關疾病之方法及配方 |
| ES2832648T3 (es) | 2016-07-08 | 2021-06-10 | CSL Behring Lengnau AG | Administración subcutánea del factor IX de acción prolongada en humanos |
| CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| CN107759697B (zh) * | 2016-08-19 | 2023-03-24 | 安源医药科技（上海）有限公司 | 制备融合蛋白的方法 |
| WO2018032638A1 (zh) | 2016-08-19 | 2018-02-22 | 安源医药科技（上海）有限公司 | 用于构建融合蛋白的连接肽 |
| BR112019011198A2 (pt) | 2016-12-02 | 2019-12-17 | Bioverativ Therapeutics Inc | métodos de indução de tolerância imune a fatores de coagulação |
| BR112019011115A2 (pt) | 2016-12-02 | 2019-10-01 | Bioverativ Therapeutics Inc. | métodos para tratar artropatia hemofílica usando fatores de coagulação quiméricos |
| US10896749B2 (en) | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
| BR112019015569A2 (pt) | 2017-01-31 | 2020-03-17 | Bioverativ Therapeutics Inc. | Proteínas de fusão do fator ix e métodos para a sua produção e uso |
| US10813589B2 (en) | 2017-06-03 | 2020-10-27 | Sentinel Medical Technologies, LLC | Catheter for monitoring uterine contraction pressure |
| US11045128B2 (en) | 2017-06-03 | 2021-06-29 | Sentinel Medical Technologies, LLC | Catheter for monitoring intra-abdominal pressure |
| US11185245B2 (en) | 2017-06-03 | 2021-11-30 | Sentinel Medical Technologies, Llc. | Catheter for monitoring pressure for muscle compartment syndrome |
| US11045143B2 (en) | 2017-06-03 | 2021-06-29 | Sentinel Medical Technologies, LLC | Catheter with connectable hub for monitoring pressure |
| US10799131B2 (en) | 2017-06-03 | 2020-10-13 | Sentinel Medical Technologies, LLC | Catheter for monitoring intrauterine pressure to protect the fallopian tubes |
| RU2020103424A (ru) | 2017-06-29 | 2021-07-29 | Цсл Беринг Ленгнау Аг | Схема введения с 21-дневными интервалами слитых белков, содержащих фактор ix и альбумин человека, для профилактического лечения гемофилии и способы такого лечения |
| JP7374883B2 (ja) | 2017-08-09 | 2023-11-07 | バイオベラティブ セラピューティクス インコーポレイテッド | 核酸分子およびその使用 |
| BR112020006149A2 (pt) | 2017-09-27 | 2020-10-20 | Sigilon Therapeutics, Inc. | célula ativa manipulada, elemento implantável, e, composição farmacêutica. |
| US20210145889A1 (en) | 2018-04-04 | 2021-05-20 | Sigilon Therapeutics, Inc. | Methods, compositions, and implantable elements comprising stem cells |
| UY38160A (es) | 2018-04-04 | 2019-11-29 | Sigilon Therapeutics Inc | Partículas implantables y métodos relacionados |
| BR112020022164A2 (pt) | 2018-05-18 | 2021-02-02 | Bioverativ Therapeutics Inc. | métodos de tratamento de hemofilia a |
| MX2021001599A (es) | 2018-08-09 | 2021-07-02 | Bioverativ Therapeutics Inc | Moleculas de acido nucleico y sus usos para la terapia genica no viral. |
| UY38389A (es) | 2018-09-27 | 2020-04-30 | Sigilon Therapeutics Inc | Dispositivos implantables para terapia celular y métodos relacionados |
| US11672457B2 (en) | 2018-11-24 | 2023-06-13 | Sentinel Medical Technologies, Llc. | Catheter for monitoring pressure |
| US11779263B2 (en) | 2019-02-08 | 2023-10-10 | Sentinel Medical Technologies, Llc. | Catheter for monitoring intra-abdominal pressure for assessing preeclampsia |
| WO2020187969A1 (en) | 2019-03-19 | 2020-09-24 | CSL Behring Lengnau AG | Factor ix variants and uses thereof in therapy |
| CA3136720A1 (en) | 2019-04-17 | 2020-10-22 | Codiak Biosciences, Inc. | Compositions of exosomes and aav |
| CN112175088B (zh) * | 2019-07-02 | 2023-03-28 | 江苏晟斯生物制药有限公司 | 改进的fix融合蛋白、缀合物及其应用 |
| WO2021026020A1 (en) | 2019-08-08 | 2021-02-11 | Sentinel Medical Technologies, LLC | Cable for use with pressure monitoring catheters |
| TW202126284A (zh) | 2019-09-30 | 2021-07-16 | 美商百歐維拉提夫治療公司 | 慢病毒載體配製物 |
| US11617543B2 (en) | 2019-12-30 | 2023-04-04 | Sentinel Medical Technologies, Llc. | Catheter for monitoring pressure |
| US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
| BR112022026127A2 (pt) | 2020-06-24 | 2023-01-17 | Bioverativ Therapeutics Inc | Métodos para remoção de fator viii livre de preparações de vetores lentivirais modificados para expressar referida proteína |
| US20240293516A1 (en) * | 2021-07-01 | 2024-09-05 | CSL Behring Lengnau AG | Factor ix subcutaneous administration with enhanced safety |
| CN120035657A (zh) | 2022-10-11 | 2025-05-23 | 西吉隆医疗股份有限公司 | 用于治疗疾病的经工程化的细胞和可植入元件 |
| JP2025534667A (ja) | 2022-10-11 | 2025-10-17 | シギロン セラピューティクス， インコーポレイテッド | 疾患治療のための改変細胞及び移植可能エレメント |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4786726A (en) * | 1986-01-06 | 1988-11-22 | Blood Systems, Inc. | Factor IX therapeutic blood product, means and methods of preparing same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US4994371A (en) | 1987-08-28 | 1991-02-19 | Davie Earl W | DNA preparation of Christmas factor and use of DNA sequences |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| US6406697B1 (en) | 1989-02-23 | 2002-06-18 | Genentech, Inc. | Hybrid immunoglobulins |
| EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
| ATE92107T1 (de) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. |
| US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| ATE194384T1 (de) | 1989-09-12 | 2000-07-15 | Hoffmann La Roche | Tnf-bindende proteine |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| ES2096749T3 (es) | 1990-12-14 | 1997-03-16 | Cell Genesys Inc | Cadenas quimericas para vias de transduccion de señal asociada a un receptor. |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| US6037452A (en) | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
| DK0615451T3 (da) | 1992-05-26 | 2006-04-24 | Immunex Corp | Hidtil ukendt cytokin der binder til CD30 |
| US6277975B1 (en) | 1992-10-23 | 2001-08-21 | Genetics Institute, Inc. | Fusions of P-selectin ligand protein and polynucleotides encoding same |
| US5621039A (en) | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
| AU689214B2 (en) | 1994-02-01 | 1998-03-26 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Fusion proteins that include antibody and nonantibody portions |
| AU3382595A (en) | 1994-07-29 | 1996-03-04 | Smithkline Beecham Corporation | Novel compounds |
| GB9415379D0 (en) | 1994-07-29 | 1994-09-21 | Smithkline Beecham Plc | Novel compounds |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| DK0805628T3 (da) | 1995-01-17 | 2003-07-14 | Brigham & Womens Hospital | Receptor specifik transepitheltransport af immunogener |
| US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| EP0904107B1 (en) | 1996-03-18 | 2004-10-20 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| CA2280700A1 (en) * | 1997-02-14 | 1998-08-20 | American Red Cross | Expression of active human factor ix in mammary tissue of transgenic animals |
| AU8679298A (en) | 1998-07-31 | 2000-02-21 | Wallace E. Carroll | Method and apparatus for determining anticoagulant therapy factors |
| US20010031721A1 (en) | 1999-05-05 | 2001-10-18 | Chandra Webb | Highly concentrated, lyophilized, and liquid factor IX formulations |
| US20030096355A1 (en) * | 1999-07-09 | 2003-05-22 | Ke Zhang | Isolation, identification and characterization of ymkz5, a novel member of the TNF-receptor supergene family |
| AU4314801A (en) | 2000-02-11 | 2001-08-20 | Lexigen Pharm Corp | Enhancing the circulating half-life of antibody-based fusion proteins |
| ES2529300T3 (es) | 2000-04-12 | 2015-02-18 | Novozymes Biopharma Dk A/S | Proteínas de fusión de albúmina |
| AU2001252084B2 (en) | 2000-04-28 | 2006-07-06 | Inflazyme Pharmaceuticals Limited | 3-nitrogen-6,7-dioxygen steroids and uses related thereto |
| WO2002040544A2 (en) | 2000-11-14 | 2002-05-23 | Board Of Regents, University Of Texas Systems | Mutant human factor ix with an increased resistance to inhibition by heparin |
| US20030203845A1 (en) | 2001-02-05 | 2003-10-30 | Knudsen Jens Bjerre | Combined use of factor VII polypeptides and factor IX polypeptides |
| EP1427820A2 (en) | 2001-09-04 | 2004-06-16 | MERCK PATENT GmbH | Modified factor ix |
| BRPI0213207B1 (pt) | 2001-10-10 | 2021-06-15 | Novo Nordisk A/S | Processo in vitro, isento de células, para a remodelagem de um peptídeo e processos para formar um conjugado entre peptídeos e um grupo de modificação |
| EP1463752A4 (en) | 2001-12-21 | 2005-07-13 | Human Genome Sciences Inc | ALBUMIN FUSION PROTEINS |
| WO2003060071A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CA2519020A1 (en) * | 2003-03-18 | 2004-09-30 | Novo Nordisk Health Care Ag | Method for the production of gla-residue containing serine proteases |
| AU2004229427A1 (en) | 2003-04-09 | 2004-10-28 | Nektar Therapeutics | Hemophilia treatment by inhalation of coagulation factors |
| EP3552627A1 (en) | 2003-05-06 | 2019-10-16 | Bioverativ Therapeutics Inc. | Clotting factor-fc chimeric proteins to treat hemophilia |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US7212798B1 (en) * | 2003-07-17 | 2007-05-01 | Cisco Technology, Inc. | Adaptive AGC in a wireless network receiver |
| JP2007501811A (ja) | 2003-08-08 | 2007-02-01 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 治療的な関心対象のタンパク質に対する遅延分子の選択的な化学物質接合のためのガラクトースオキシダーゼの使用。 |
| WO2005037867A1 (en) * | 2003-10-15 | 2005-04-28 | Pdl Biopharma, Inc. | ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG |
| WO2005055950A2 (en) | 2003-12-03 | 2005-06-23 | Neose Technologies, Inc. | Glycopegylated factor ix |
| WO2006018204A1 (en) | 2004-08-17 | 2006-02-23 | Zlb Behring Gmbh | Modified vitamin k dependent polypeptides |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| JP2008523837A (ja) | 2004-12-21 | 2008-07-10 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | ガンマ―カルボキシル化に欠陥のある宿主系におけるガンマ―カルボキシル化ポリペプチドの発現 |
| US20060162552A1 (en) | 2005-01-26 | 2006-07-27 | Mohawk Valley Energy Solutions, Inc. | Systems and methods for controlling room air quality |
| EP2975135A1 (en) | 2005-05-25 | 2016-01-20 | Novo Nordisk A/S | Glycopegylated factor IX |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| WO2007103515A2 (en) | 2006-03-06 | 2007-09-13 | Amunix, Inc. | Unstructured recombinant polymers and uses thereof |
| BRPI0618133A2 (pt) | 2005-11-01 | 2011-08-16 | Wyeth Corp | solução de cloreto de sódio para reconstituição ou diluição de droga |
| US8759292B2 (en) | 2006-02-03 | 2014-06-24 | Prolor Biotech, Llc | Long-acting coagulation factors and methods of producing same |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| EP2004683B1 (en) | 2006-03-24 | 2016-05-11 | Biogen Hemophilia Inc. | Pc5 as a factor ix propeptide processing enzyme |
| WO2007115724A2 (en) * | 2006-04-11 | 2007-10-18 | Csl Behring Gmbh | Method of increasing the in vivo recovery of therapeutic polypeptides |
| US20090252720A1 (en) | 2006-05-24 | 2009-10-08 | Novo Nordisk Health Care Ag | Prolonged FIX Analogues and Derivatives |
| US7939632B2 (en) | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
| DK3896090T3 (da) | 2006-06-14 | 2022-03-21 | Csl Behring Gmbh | Proteolytisk spalteligt fusionsprotein omfattende en blodkoagutionsfaktor |
| TW200804416A (en) | 2006-06-19 | 2008-01-16 | Nautilus Technology Llc | Modified coagulation factor IX polypeptides and use thereof for treatment |
| WO2008009635A2 (en) | 2006-07-17 | 2008-01-24 | Novo Nordisk Health Care Ag | Factor viia analogues with increased activity for treating thrombocytopenia |
| WO2008022151A1 (en) | 2006-08-15 | 2008-02-21 | Inspiration Biopharmaceuticals, Inc. | Prophylactic treatment of hemophilia |
| CN101646689A (zh) * | 2006-09-08 | 2010-02-10 | 埃博灵克斯股份有限公司 | 具有长半衰期的血清清蛋白结合蛋白 |
| US7700734B2 (en) | 2007-01-09 | 2010-04-20 | Shu-Wha Lin | Recombinant human factor IX and use thereof |
| WO2008119815A1 (en) | 2007-04-02 | 2008-10-09 | Novo Nordisk A/S | Subcutaneous administration of coagulation factor ix |
| CN103298935A (zh) | 2007-08-15 | 2013-09-11 | 阿穆尼克斯公司 | 用于改善生物活性多肽性能的组合物和方法 |
| CN102026653B (zh) | 2007-10-15 | 2014-06-18 | 北卡罗来纳-查佩尔山大学 | 半衰期延长的人因子ⅸ变体 |
| JP2011517950A (ja) | 2008-04-16 | 2011-06-23 | バイエル・ヘルスケア・エルエルシー | 第ｉｘ因子の部位特異的修飾 |
| WO2009137254A2 (en) | 2008-04-16 | 2009-11-12 | Bayer Healthcare Llc | Modified factor ix polypeptides and uses thereof |
| WO2009130198A2 (en) | 2008-04-21 | 2009-10-29 | Novo Nordisk A/S | Hyperglycosylated human coagulation factor ix |
| AU2009239641B2 (en) * | 2008-04-24 | 2013-11-07 | Cantab Biopharmaceuticals Patents Limited | Factor IX conjugates with extended half-lives |
| US20090282865A1 (en) | 2008-05-16 | 2009-11-19 | Ortloff Engineers, Ltd. | Liquefied Natural Gas and Hydrocarbon Gas Processing |
| MX2011001624A (es) * | 2008-08-21 | 2011-03-28 | Octapharma Ag | Factor viii y ix humano producido en forma recombinante. |
| CN102164943A (zh) | 2008-09-24 | 2011-08-24 | 稳定技术有限公司 | 使用糖和聚乙烯亚胺保存多肽的方法 |
| WO2010091122A1 (en) * | 2009-02-03 | 2010-08-12 | Amunix, Inc. | Extended recombinant polypeptides and compositions comprising same |
| CN102317315A (zh) | 2009-02-11 | 2012-01-11 | 诺维信生物制药丹麦公司 | 白蛋白变体和缀合物 |
| WO2011030641A1 (ja) | 2009-09-08 | 2011-03-17 | コニカミノルタホールディングス株式会社 | 身体用装具 |
| WO2011051489A2 (en) | 2009-10-30 | 2011-05-05 | Novozymes Biopharma Dk A/S | Albumin variants |
| EP2353588B1 (en) | 2010-01-21 | 2015-04-15 | Agricultural Technology Research Institute | A sustained release preparation of factor IX |
| US10233228B2 (en) | 2010-04-09 | 2019-03-19 | Albumedix Ltd | Albumin derivatives and variants |
| EA028067B1 (ru) | 2010-07-09 | 2017-10-31 | Байоджен Хемофилия Инк. | Способы контроля или предотвращения кровотечения или эпизодов кровотечения |
| CN110272484A (zh) | 2011-05-05 | 2019-09-24 | 阿尔布梅迪克斯医疗有限公司 | 白蛋白变体 |
| HK1200842A1 (en) | 2011-11-18 | 2015-08-14 | Albumedix Ltd | Proteins with improved half-life and other properties |
| WO2014052490A1 (en) | 2012-09-25 | 2014-04-03 | Biogen Idec Ma Inc. | Methods of using fix polypeptides |
| US20160033523A1 (en) | 2013-02-16 | 2016-02-04 | Novozymes Biopharma Dk A/S | Pharmacokinetic animal model |
| TWI788044B (zh) | 2013-03-15 | 2022-12-21 | 美商百歐維拉提夫治療公司 | 因子ｉｘ多肽調配物 |
| CN105848669A (zh) | 2013-12-23 | 2016-08-10 | 杰特有限公司 | 用于血友病的预防性治疗的包含因子ix的融合蛋白及其方法 |
-
2011
- 2011-07-11 EA EA201291480A patent/EA028067B1/ru unknown
- 2011-07-11 JP JP2013518876A patent/JP2013534426A/ja active Pending
- 2011-07-11 NZ NZ605348A patent/NZ605348A/en unknown
- 2011-07-11 MX MX2017008224A patent/MX375112B/es unknown
- 2011-07-11 UA UAA201301039A patent/UA115120C2/uk unknown
- 2011-07-11 MY MYPI2013000037A patent/MY166954A/en unknown
- 2011-07-11 PL PL19156074.7T patent/PL3552619T3/pl unknown
- 2011-07-11 EP EP11804476.7A patent/EP2590668A4/en not_active Withdrawn
- 2011-07-11 PT PT191560747T patent/PT3552619T/pt unknown
- 2011-07-11 EA EA201790876A patent/EA037095B1/ru unknown
- 2011-07-11 WO PCT/US2011/043569 patent/WO2012006624A2/en not_active Ceased
- 2011-07-11 BR BR112013000650A patent/BR112013000650A8/pt not_active Application Discontinuation
- 2011-07-11 MX MX2013000281A patent/MX356527B/es active IP Right Grant
- 2011-07-11 DK DK19156074.7T patent/DK3552619T3/da active
- 2011-07-11 AU AU2011274414A patent/AU2011274414B2/en active Active
- 2011-07-11 KR KR1020237037701A patent/KR20230156435A/ko not_active Ceased
- 2011-07-11 KR KR1020187030651A patent/KR20180118808A/ko not_active Ceased
- 2011-07-11 SG SG10201913700SA patent/SG10201913700SA/en unknown
- 2011-07-11 LT LTEP19156074.7T patent/LT3552619T/lt unknown
- 2011-07-11 UA UAA201701696A patent/UA126265C2/uk unknown
- 2011-07-11 CN CN2011800375149A patent/CN103140237A/zh active Pending
- 2011-07-11 SG SG10201505218YA patent/SG10201505218YA/en unknown
- 2011-07-11 FI FIEP19156074.7T patent/FI3552619T3/fi active
- 2011-07-11 KR KR1020227020222A patent/KR20220097518A/ko not_active Ceased
- 2011-07-11 CA CA2804274A patent/CA2804274A1/en active Pending
- 2011-07-11 RS RS20251092A patent/RS67366B1/sr unknown
- 2011-07-11 KR KR1020197025541A patent/KR20190104442A/ko not_active Ceased
- 2011-07-11 MY MYPI2017000477A patent/MY192639A/en unknown
- 2011-07-11 US US13/809,276 patent/US9670475B2/en active Active
- 2011-07-11 EP EP19156074.7A patent/EP3552619B1/en active Active
- 2011-07-11 KR KR1020137003411A patent/KR20140017480A/ko not_active Ceased
- 2011-07-11 SG SG2012096053A patent/SG186856A1/en unknown
- 2011-07-11 EP EP25189951.4A patent/EP4653528A2/en active Pending
-
2012
- 2012-12-30 IL IL223990A patent/IL223990B/en active IP Right Grant
-
2013
- 2013-01-08 CL CL2013000058A patent/CL2013000058A1/es unknown
- 2013-01-08 MX MX2020009702A patent/MX2020009702A/es unknown
- 2013-03-11 US US13/793,796 patent/US9233145B2/en active Active
-
2015
- 2015-11-17 JP JP2015224436A patent/JP2016034973A/ja active Pending
- 2015-12-29 US US14/982,934 patent/US9867873B2/en active Active
-
2016
- 2016-02-12 US US15/043,445 patent/US9675676B2/en active Active
- 2016-02-12 US US15/043,457 patent/US9629903B2/en active Active
- 2016-02-12 US US15/043,455 patent/US9623091B2/en active Active
- 2016-09-15 AU AU2016228243A patent/AU2016228243B2/en active Active
- 2016-11-09 JP JP2016218597A patent/JP2017036328A/ja not_active Withdrawn
-
2017
- 2017-11-21 US US15/820,080 patent/US20180207244A1/en not_active Abandoned
- 2017-11-30 AU AU2017268650A patent/AU2017268650B2/en active Active
-
2018
- 2018-02-06 US US15/890,284 patent/US10561714B2/en active Active
- 2018-02-06 US US15/890,290 patent/US20180228879A1/en not_active Abandoned
- 2018-11-21 JP JP2018218122A patent/JP2019023242A/ja not_active Withdrawn
-
2019
- 2019-02-08 US US16/271,686 patent/US10568943B2/en active Active
- 2019-02-08 US US16/271,689 patent/US10548954B2/en active Active
-
2020
- 2020-01-08 AU AU2020200118A patent/AU2020200118B2/en active Active
- 2020-06-22 US US16/907,985 patent/US20210008178A1/en not_active Abandoned
- 2020-09-17 IL IL277432A patent/IL277432B/en unknown
- 2020-09-25 US US17/032,354 patent/US10898554B1/en active Active
-
2021
- 2021-06-24 IL IL284368A patent/IL284368A/en unknown
-
2022
- 2022-01-31 JP JP2022012817A patent/JP2022044828A/ja active Pending
- 2022-06-29 AU AU2022204643A patent/AU2022204643B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013534426A5 (enExample) | ||
| JP7741145B2 (ja) | 第ｉｘ因子ポリペプチド製剤 | |
| US9730984B2 (en) | Composition for preventing or treating rheumatoid arthritis | |
| JP2016516722A5 (enExample) | ||
| HRP20220639T1 (hr) | Kimerni i hibridni polipeptidi faktora viii i postupci njihove upotrebe | |
| JP2009545313A5 (enExample) | ||
| JP2010518079A5 (enExample) | ||
| JP2011530599A5 (enExample) | ||
| EP3575314A2 (en) | Glucagon derivatives | |
| US12018060B2 (en) | Glucagon derivatives | |
| CN107847565B (zh) | 用于肌肉减少症治疗的包括胰高血糖素样肽-1受体激动剂的药物组合物 | |
| ES2700149T3 (es) | Proteínas de fusión de UTI | |
| Gao et al. | Calcium activated potassium channel and protein kinase C participate in the cardiac protection of remote post conditioning. | |
| CN113423466B (zh) | 软骨病症的治疗剂 | |
| AU2022207001B2 (en) | Application of cilostazol-containing composition in preparing drug for treating cerebrovascular disease | |
| JP6057314B2 (ja) | 加療中動物の回復促進治療剤 | |
| CN104211778A (zh) | 一种转化生长因子β1激动剂多肽及其制备方法、应用 | |
| KR20180027924A (ko) | 글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물 | |
| WO2025110141A1 (ja) | 睡眠改善剤 | |
| TW202409064A (zh) | 用於治療疼痛的肽和方法 | |
| JPWO2022243932A5 (enExample) | ||
| CN114113623A (zh) | Cxcl12/cxcr4信号通路作为靶点在制备治疗或预防异位骨化的药物中的应用 | |
| HK40010066A (en) | Glucagon derivative | |
| KR20170041116A (ko) | 신경계의 보호 및/또는 복구용 조성물 및 방법 | |
| CN1764470A (zh) | 促红细胞生成素在中风康复中的用途 |